ProQR Therapeutics NV
PRQR2.095USD
+0.015+0.72%
Horário de mercado （ET）Cotações atrasadas em 15 min
225.65MValor de mercado
PerdaP/L TTM
Mais detalhes de ProQR Therapeutics NV Empresa
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Informações da empresa
Código da empresaPRQR
Nome da EmpresaProQR Therapeutics NV
Data de listagemSep 18, 2014
CEOMr. Daniel Anton de Boer
Número de funcionários166
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 18
EndereçoZernikedreef 9
CidadeLEIDEN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísNetherlands
Código postal2333 CK
Telefone31881667000
Sitehttps://www.proqr.com/
Código da empresaPRQR
Data de listagemSep 18, 2014
CEOMr. Daniel Anton de Boer
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Begona Carreno, Ph.D.
Ms. Begona Carreno, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
-100.00%
Dr. Martin Maier, Ph.D.
Dr. Martin Maier, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
Investidores
Investidores
Proporção
Eli Lilly and Company
16.06%
Van Herk Investments
10.93%
Adage Capital Management, L.P.
7.70%
Privium Fund Management BV
4.75%
Affinity Asset Advisors LLC
3.12%
Other
57.44%
Tipos de investidores
Investidores
Proporção
Hedge Fund
21.84%
Corporation
16.06%
Investment Advisor
11.42%
Family Office
10.93%
Investment Advisor/Hedge Fund
4.91%
Individual Investor
2.00%
Research Firm
1.72%
Bank and Trust
0.04%
Venture Capital
0.02%
Other
31.06%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
122
61.04M
58.02%
-5.87M
2025Q1
131
62.09M
59.01%
-3.97M
2024Q4
135
61.46M
58.04%
+24.32M
2024Q3
126
39.02M
42.64%
-5.37M
2024Q2
127
38.86M
42.67%
-6.74M
2024Q1
137
38.95M
43.54%
-15.29M
2023Q4
162
39.95M
44.78%
-23.51M
2023Q3
167
40.45M
49.96%
-14.58M
2023Q2
170
45.68M
56.49%
-13.40M
2023Q1
180
47.05M
58.19%
-9.38M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Eli Lilly and Company
16.90M
16.06%
+3.52M
+26.35%
Dec 31, 2024
Van Herk Investments
11.50M
10.93%
+40.00K
+0.35%
May 23, 2025
Adage Capital Management, L.P.
8.10M
7.7%
-1.50M
-15.62%
Mar 31, 2025
Privium Fund Management BV
4.99M
4.74%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
3.28M
3.12%
+459.51K
+16.27%
Mar 31, 2025
Millennium Management LLC
2.07M
1.97%
-756.63K
-26.76%
Mar 31, 2025
Sio Capital Management, LLC
2.05M
1.95%
--
--
Mar 31, 2025
abrdn Inc.
1.85M
1.76%
+1.85M
--
Mar 31, 2025
UBS Financial Services, Inc.
1.78M
1.69%
-511.49K
-22.30%
Mar 31, 2025
Kynam Capital Management LP
1.75M
1.66%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Avantis International Small Cap Value ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis International Small Cap Equity ETF
0%
Avantis International Small Cap Value ETF
Proporção0%
Invesco NASDAQ Future Gen 200 ETF
Proporção0%
Avantis International Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
